Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

U.S. researchers report significant advance in gene therapy for hearing disorders

Feb. 11, 1997

Takeda prepares NO production inhibitors

Feb. 11, 1997

U.S. and European investigators describe agents for CNS disorders

Feb. 11, 1997

Spiro compounds for CNS disorders disclosed by Takeda

Feb. 11, 1997

BioSpecifics Technologies is issued 9th U.S. patent for use of collagenase enzyme

Feb. 10, 1997

Launch date for Aricept revealed

Feb. 10, 1997

Analgesic/antiinflammatory agent from Merck KGaA

Feb. 10, 1997

Gruenenthal prepares analgesics

Feb. 10, 1997

Potential anticonvulsant described by CoCensys

Feb. 7, 1997

Abbott's newest dopaminergic compounds described in patent literature

Feb. 6, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...